Google’s AI for Science Gambit Pressures Big Pharma & Cloud Rivals

Google is repositioning its AI capabilities beyond foundational models, focusing on high-value scientific R&D in a direct challenge to specialized incumbents. By open-sourcing models for drug discovery, weather forecasting, and genomics, Google is commoditizing the base layer of scientific AI. This move mirrors DeepMind’s AlphaFold strategy but at a portfolio level, aiming to create a new competitive axis centered on vertical-specific applications. This fundamentally alters the build-vs-buy calculation for enterprises in life sciences and materials science, pressuring both startups and established software providers who previously owned these niche workflows. The immediate effect is a strategic recalculation for companies like Schrödinger and Dassault Systèmes, whose business models rely on proprietary simulation and modeling software. Google’s open-source releases, such as AlphaFold2 and GraphCast, create an asymmetric advantage by driving scientific breakthroughs that indirectly funnel users toward Google Cloud for scaled implementation. This exposes a vulnerability in rivals like AWS and Azure, who may offer more generic compute but lack the deeply integrated, domain-specific models needed to capture the lucrative scientific research market, which is projected to spend over $20 billion on AI tools by 2028. The trajectory suggests a future where winning in AI is not about the largest model, but the most impactful application ecosystem. Over the next 12-24 months, the real test will be adoption rates within university labs and biotech startups—if they build critical workflows on Google’s tools, it will create a powerful moat. This forces a strategic choice for the industry: either double down on foundational model leadership or pivot to building defensible, vertical-specific AI applications. The critical variable is whether the promise of open-source science can overcome the enterprise demand for vendor stability and support.